SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021)
SELLAS Life Sciences (SLS) reported Current Deferred Revenue of $900000.0 for Q1 2021, down 83.93% on a QoQ basis from $5.6 million in Q4 2020.
SELLAS Life Sciences (SLS) has 3 years of Current Deferred Revenue data on file, last reported at $900000.0 in Q1 2021.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $900000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $900000.0 (changed N/A YoY) and the FY2020 annual result came in at $5.6 million, changed N/A from the prior year.
- Current Deferred Revenue eased to $900000.0 in Q1 2021 per SLS's latest filing, from $5.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $5.6 million in Q4 2020 and bottomed at $900000.0 in Q1 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 900,000.00 |
| Dec 31, 2020 | 5.60 Mn |
| Dec 31, 2011 | 816,000.00 |
| Sep 30, 2011 | 877,000.00 |
| Jun 30, 2011 | 578,000.00 |